Geron Corporation (GERN)
Market Closed
20 Jul, 20:00
$
1. 44
0
0%
$
923.79M Market Cap
- P/E Ratio
- Div Yield
5.15M Volume
-0.34 Eps
$ 1.44
Previous Close 
Want to track GERN and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Geron shares surge after U.S. FDA approves blood disorder drug
Shares of Geron rose almost 16% on Friday before market, a day after getting its first approval from the U.S. Food and Drug Administration for a drug to treat transfusion-dependent anemia in patients with a group of blood cancers.
Reuters | 2 years ago
Geron Corporation: A High-Risk Deal With A Good Chance Of Success
Geron Corporation's unique product, Imetelstat, could potentially bring real benefits to hematological diseases with a Total Addressable Market value of $7 billion by 2031. Clinical studies have shown statistical evidence supporting the effectiveness of Imetelstat in inhibiting telomerase and treating diseases. The FDA Oncologic Drugs Advisory Committee voted in favor of Imetelstat (12 to 2) for patients with MDS.
Seekingalpha | 2 years ago
